The purpose of this research study titled Vascular Grafts Market - Growth, Future Prospects, and Competitive Analysis, 2022 - 2030 is to provide investors, developers, company executives, and industry participants with in-depth analysis to allow them to take strategic initiatives and decisions related to the prospects in the global vascular grafts market. This report presents and analyzes the major trends prevalent in the global vascular grafts market and the market size and forecast.
This report categorizes the global vascular grafts market in terms of type, material, application, and geographical distribution. Based on product type, the global vascular grafts market is categorized into endovascular stent grafts, peripheral vascular grafts, hemodialysis access grafts, and coronary artery by-pass graft. Synthetic (polytetrafluethylene (PTFE), polyurethane (PU), dacron, and others), biological (saphenous vein, bovine vein and others) and biosynthetic are the various vascular grafts materials studied in this report. In terms of application areas, vascular grafts find wide usage in treatment for cardiovascular diseases, aneurysm, kidney failure, vascular occlusion, and diabetes.
This report also includes qualitative assessment factors such as market dynamics (drivers, restraints, and opportunities) to have a good understanding of the current and anticipated trends in the global vascular grafts market. Competition assessment tools such as market attractiveness assessment and competitive landscape analysis by key players are also demonstrated in the study. Furthermore, this report concludes with profiling of key market players currently enjoying prominent position in the vascular grafts market. The key players profiled in this report are Artegraft, Inc., B. Braun Melsungen AG, Cook Medical, Inc., C.R. Bard, Inc., CryoLife, Inc., Heart Medical Europe BV, Japan Lifeline Co., Ltd. (Junken Medical Co., Ltd), LeMaitre Vascular, Inc., MAQUET Holding B.V. & Co. KG, Medtronic plc, Shanghai Suokang Medical Implants Co. Ltd., Terumo Medical Corporation, Vascular Grafts Solutions Ltd., Vascutek Ltd. and W. L. Gore & Associates, Inc.
In 2021, endovascular stent grafts occupied the largest share of the overall vascular grafts market. Major factors influencing its dominance include growing risk of chronic diseases such as renal conditions, cardiovascular diseases and diabetes due to lifestyle changes, occupational factors and dietary habits. Furthermore, growing prevalence of hypertension and age-related chronic conditions has additionally urged the need for endovascular grafts and coronary artery by-pass grafts in the market. Additionally, recent development in vascular tissue engineering has resulted in creation of cell-free grafts that are available on demand. However, restraints associated with cell-based grafts such as cell expansion, long-term bioreactor culture and cell sourcing has motivated introduction of completely cell-free vascular grafts.
In 2021, cardiovascular diseases accounted for over 20% of the global vascular grafts market on account of growing prevalence of hypertension, and other age-related cardiovascular diseases, with the highest prevalence of coronary artery diseases. Cardiovascular diseases are often associated with blockage or narrowing of blood vessels and reduced blood flow. By 2032, CVD mortality will be predicted to cross 23 Mn mark. Vascular surgery is often recommended for treatment of CVDs when pharmaceutical administration, and dietary and lifestyle modifications prove inadequate. Vascular grafts may be used to bypass or replace damaged vessel. At present, most favored conduits for cardiovascular grafting are autologous arteries or veins, saphenous vein being the most common autograft option. Despite being the gold standard for grafting, saphenous vein grafting presents limited patency. Additionally, synthetic vascular grafts though available as an alternative to autologous grafts are used less due to poor patency rates.
Geographically, the global vascular grafts market is cumulative to North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.
North America is the largest regional market for vascular grafts and will continue to dominate the global market. High prevalence of chronic diseases such as diabetes, cardiovascular diseases and end-stage renal diseases and the corresponding growth in demand for surgical treatments largely contribute to the domination of North America market. Existence of developed healthcare system, favorable reimbursements and greater awareness about treatment and management of chronic diseases are major features of North America market. Additionally, Asia Pacific is anticipated to be the fastest processing market for vascular grafts during the forecast period. Rapid evolution of healthcare systems and growing penetration of major market players in the light of increasing healthcare expenditure greatly attribute to the movement of Asia Pacific market.
At present synthetic grafts are observed to be the most preferred type worldwide. Polytetrafluethylene, Polyurethane, Dacron, etc. are highly preferred in most grafting procedures. Easy availability, lesser cost, higher tensile strength are some of the factors attributing to larger market share of synthetic materials. However, biological materials have higher demand in cardiovascular treatments and are expected to be the fastest growing segment. Growing awareness about benefits of biological grafts in terms of acceptance, biocompatibility and technological advancement are the key factors contributing to the emergence of biological materials. At present internal thoracic artery and saphenous vein are the gold standard grafts used for cardiovascular procedures are outperform synthetic alternatives. However, limited availability of these grafts challenge their widespread use. To address this challenge, tissue-engineered vascular grafts (TEVG) are being rigorously explored. TEVG have offered benefits such as ability to remodel, grow and repair in-vivo without needing autograft surgery.
The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
This product will be delivered within 2 business days.
This report categorizes the global vascular grafts market in terms of type, material, application, and geographical distribution. Based on product type, the global vascular grafts market is categorized into endovascular stent grafts, peripheral vascular grafts, hemodialysis access grafts, and coronary artery by-pass graft. Synthetic (polytetrafluethylene (PTFE), polyurethane (PU), dacron, and others), biological (saphenous vein, bovine vein and others) and biosynthetic are the various vascular grafts materials studied in this report. In terms of application areas, vascular grafts find wide usage in treatment for cardiovascular diseases, aneurysm, kidney failure, vascular occlusion, and diabetes.
This report also includes qualitative assessment factors such as market dynamics (drivers, restraints, and opportunities) to have a good understanding of the current and anticipated trends in the global vascular grafts market. Competition assessment tools such as market attractiveness assessment and competitive landscape analysis by key players are also demonstrated in the study. Furthermore, this report concludes with profiling of key market players currently enjoying prominent position in the vascular grafts market. The key players profiled in this report are Artegraft, Inc., B. Braun Melsungen AG, Cook Medical, Inc., C.R. Bard, Inc., CryoLife, Inc., Heart Medical Europe BV, Japan Lifeline Co., Ltd. (Junken Medical Co., Ltd), LeMaitre Vascular, Inc., MAQUET Holding B.V. & Co. KG, Medtronic plc, Shanghai Suokang Medical Implants Co. Ltd., Terumo Medical Corporation, Vascular Grafts Solutions Ltd., Vascutek Ltd. and W. L. Gore & Associates, Inc.
In 2021, endovascular stent grafts occupied the largest share of the overall vascular grafts market. Major factors influencing its dominance include growing risk of chronic diseases such as renal conditions, cardiovascular diseases and diabetes due to lifestyle changes, occupational factors and dietary habits. Furthermore, growing prevalence of hypertension and age-related chronic conditions has additionally urged the need for endovascular grafts and coronary artery by-pass grafts in the market. Additionally, recent development in vascular tissue engineering has resulted in creation of cell-free grafts that are available on demand. However, restraints associated with cell-based grafts such as cell expansion, long-term bioreactor culture and cell sourcing has motivated introduction of completely cell-free vascular grafts.
In 2021, cardiovascular diseases accounted for over 20% of the global vascular grafts market on account of growing prevalence of hypertension, and other age-related cardiovascular diseases, with the highest prevalence of coronary artery diseases. Cardiovascular diseases are often associated with blockage or narrowing of blood vessels and reduced blood flow. By 2032, CVD mortality will be predicted to cross 23 Mn mark. Vascular surgery is often recommended for treatment of CVDs when pharmaceutical administration, and dietary and lifestyle modifications prove inadequate. Vascular grafts may be used to bypass or replace damaged vessel. At present, most favored conduits for cardiovascular grafting are autologous arteries or veins, saphenous vein being the most common autograft option. Despite being the gold standard for grafting, saphenous vein grafting presents limited patency. Additionally, synthetic vascular grafts though available as an alternative to autologous grafts are used less due to poor patency rates.
Geographically, the global vascular grafts market is cumulative to North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.
North America is the largest regional market for vascular grafts and will continue to dominate the global market. High prevalence of chronic diseases such as diabetes, cardiovascular diseases and end-stage renal diseases and the corresponding growth in demand for surgical treatments largely contribute to the domination of North America market. Existence of developed healthcare system, favorable reimbursements and greater awareness about treatment and management of chronic diseases are major features of North America market. Additionally, Asia Pacific is anticipated to be the fastest processing market for vascular grafts during the forecast period. Rapid evolution of healthcare systems and growing penetration of major market players in the light of increasing healthcare expenditure greatly attribute to the movement of Asia Pacific market.
At present synthetic grafts are observed to be the most preferred type worldwide. Polytetrafluethylene, Polyurethane, Dacron, etc. are highly preferred in most grafting procedures. Easy availability, lesser cost, higher tensile strength are some of the factors attributing to larger market share of synthetic materials. However, biological materials have higher demand in cardiovascular treatments and are expected to be the fastest growing segment. Growing awareness about benefits of biological grafts in terms of acceptance, biocompatibility and technological advancement are the key factors contributing to the emergence of biological materials. At present internal thoracic artery and saphenous vein are the gold standard grafts used for cardiovascular procedures are outperform synthetic alternatives. However, limited availability of these grafts challenge their widespread use. To address this challenge, tissue-engineered vascular grafts (TEVG) are being rigorously explored. TEVG have offered benefits such as ability to remodel, grow and repair in-vivo without needing autograft surgery.
Historical & Forecast Period
This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
Research Methodology
The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Vascular Grafts market are as follows:- Research and development budgets of manufacturers and government spending
- Revenues of key companies in the market segment
- Number of end users and consumption volume, price and value.
- Geographical revenues generate by countries considered in the report
- Micro and macro environment factors that are currently influencing the Vascular Grafts market and their expected impact during the forecast period.
Market Segmentation
Type
- Endovascular Stent Grafts
- Peripheral Vascular Grafts
- Hemodialysis Access Grafts
- Coronary Artery By-pass Grafts
Material
- Synthetic
- Polytetrafluethylene (PTFE)
- Polyurethane (PU)
- Dacron
- Others
- Biological
- Saphenous Vein
- Bovine Vein
- Others
- Biosynthetic
Application
- Cardiovascular Diseases
- Aneurysm
- Kidney Failure
- Vascular Occlusion
- Diabetes
Key questions answered in this report
- What are the key micro and macro environmental factors that are impacting the growth of Vascular Grafts market?
- What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
- Estimated forecast and market projections up to 2030.
- Which segment accounts for the fastest CAGR during the forecast period?
- Which market segment holds a larger market share and why?
- Are low and middle-income economies investing in the Vascular Grafts market?
- Which is the largest regional market for Vascular Grafts market?
- What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
- Which are the key trends driving Vascular Grafts market growth?
- Who are the key competitors and what are their key strategies to enhance their market presence in the Vascular Grafts market worldwide?
This product will be delivered within 2 business days.
Table of Contents
1. Preface
2. Executive Summary
3. Vascular Grafts Market: Business Outlook & Market Dynamics
4. Vascular Grafts Market: By Type, 2020-2030, USD (Million)
5. Vascular Grafts Market: By Material, 2020-2030, USD (Million)
6. Vascular Grafts Market: By Application, 2020-2030, USD (Million)
7. North America Vascular Grafts Market, 2020-2030, USD (Million)
8. UK and European Union Vascular Grafts Market, 2020-2030, USD (Million)
9. Asia Pacific Vascular Grafts Market, 2020-2030, USD (Million)
10. Latin America Vascular Grafts Market, 2020-2030, USD (Million)
11. Middle East and Africa Vascular Grafts Market, 2020-2030, USD (Million)
12. Company Profile
List of Figures
Companies Mentioned
- Artegraft Inc.
- B. Braun Melsungen AG
- Cook Medical Inc.
- C.R. Bard Inc.
- CryoLife Inc.
- Heart Medical Europe BV
- Japan Lifeline Co. Ltd. (Junken Medical Co. Ltd.
- LeMaitre Vascular Inc.
- MAQUET Holding B.V. & Co. KG
- Medtronic plc
- Shanghai Su